|
|
Watson News (NYSE:WPI)
| Latest Watson Pharmaceuticals News Headlines | | Date | Time | Source | | | 11/26/2008 | 4:00PM | PRNUS | Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
CORONA, Calif., Nov. 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received final approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application... More...>> |
| 11/25/2008 | 8:00AM | PRNUS | Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
CORONA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between Teva Pharmaceutical... More...>> |
| 11/13/2008 | 4:00PM | PRNUS | Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prost
CORONA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for a 6-month formulation of TRELSTAR(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted... More...>> |
| 10/29/2008 | 7:00AM | PRNUS | Watson Pharmaceuticals Reports Third Quarter 2008 Results
Total Net Revenue of $641 Million; GAAP EPS $0.62; Adjusted EPS $0.47
CORONA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2008.
Third Quarter 2008 Results
Net... More...>> |
| 10/09/2008 | 8:30AM | PRNUS | UPDATE: Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
- RAPAFLO launch anticipated in early 2009 -
CORONA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM) (silodosin), the company's new alpha blocker for... More...>> |
| 10/08/2008 | 6:00PM | PRNUS | Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
- RAPAFLO launch anticipated in early 2009 -
CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM) (silodosin), the company's new alpha blocker for... More...>> |
| 10/08/2008 | 8:30AM | PRNUS | Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's
- New Research shows that oxybutynin topical gel may be a convenient alternative to currently available treatments for OAB -
CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical pharmacokinetic... More...>> |
| 10/01/2008 | 5:03PM | PRNUS | Watson Notified of OXYTROL(R) Patent Challenge
CORONA, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today confirmed the receipt of a Paragraph IV Certification Notice Letter relating to an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA... More...>> |
| 09/29/2008 | 8:30AM | PRNUS | Watson Announces Positive Data for RAPAFLO(TM)(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences
- Results demonstrate the efficacy, safety and tolerability of RAPAFLO(TM) alone or in combination with treatments for erectile dysfunction -
CORONA, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that investigators presented... More...>> |
| 08/13/2008 | 9:46PM | PRNUS | Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes... More...>> |
| 08/06/2008 | 7:00AM | PRNUS | Watson Pharmaceuticals Reports Second Quarter 2008 Results
Total Net Revenue of $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48
CORONA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2008.
Second Quarter 2008 Results
Net revenue... More...>> |
| 08/05/2008 | 8:00AM | PRNUS | Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes
- QTc profile particularly important among BPH patients with cardiovascular risk factors -
CORONA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- A paper published in the current issue of Reviews in Urology (2008; 10(2):85-91) concludes that urologists and other physicians treating benign prostatic hyperplasia (BPH) should... More...>> |
| 07/28/2008 | 5:16PM | PRNUS | Mylan Acquires Remaining Interest in Somerset Joint Venture From Watson
PITTSBURGH and CORONA, Calif., July 28 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE:MYL) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that Mylan has acquired Watson's 50 percent interest in the Somerset Pharmaceuticals, Inc. (Somerset) joint venture. Details of the transaction remain confidential.
Somerset... More...>> |
| 07/28/2008 | 8:00AM | PRNUS | Watson Names Clare Carmichael Senior VP Human Resources
CORONA, Calif., July 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced the appointment of Clare Carmichael as Senior Vice President, Human Resources. Ms. Carmichael's appointment follows the planned retirement of long-time industry professional... More...>> |
| 07/25/2008 | 8:00AM | PRNUS | Watson Launches Omeprazole Delayed-Release Capsules, 40MG
- 180-Days of Marketing Exclusivity Begins -
CORONA, Calif., July 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that its subsidiary has commenced commercial shipment of its Omeprazole Delayed-Release Capsules USP product in the 40mg... More...>> |
| 06/30/2008 | 1:30AM | PRNUS | Watson Launches Generic MARINOL(R) Capsules
CORONA, Calif., June 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily... More...>> |
| 06/03/2008 | 7:30AM | PRNUS | Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
CORONA, Calif., June 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Potassium-Chloride Extended-Release... More...>> |
| 06/02/2008 | 8:00AM | PRNUS | Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that it has received final approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Capsules... More...>> |
| 05/28/2008 | 3:00AM | PRNUS | Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
CORONA, Calif., May 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that its New Drug Application (NDA) for oxybutynin chloride topical gel (OTG), has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking... More...>> |
| 05/23/2008 | 5:58PM | PRNUS | Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
CORONA, Calif., May 23 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the UBS Global Specialty and Generic... More...>> |
|
|
|